{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:06:36Z","timestamp":1773234396536,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","annalsofvascularsurgery.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.avsg.2017.11.037","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T03:09:09Z","timestamp":1518750549000},"page":"313.e1-313.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Ocular Myasthenia Induced by Rivaroxaban in Patient with Deep Vein Thrombosis"],"prefix":"10.1016","volume":"49","author":[{"given":"Enrique M.","family":"San Norberto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Garc\u00eda-Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Domingos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2017.11.037_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1076029616631427","article-title":"Evidence-based development and rationale for once-daily rivaroxaban dosing regimens across multiple indications","volume":"22","author":"Kubitza","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.avsg.2017.11.037_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drugs reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.avsg.2017.11.037_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3988\/jcn.2011.7.4.173","article-title":"Treatment of myasthenia gravis based on its immunopathogenesis","volume":"7","author":"Kim","year":"2011","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.avsg.2017.11.037_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/CND.0b013e318285257f","article-title":"Pegylated interferon induced myasthenia crisis: a case report","volume":"14","author":"Congeni","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.avsg.2017.11.037_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.avsg.2017.11.037_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/0022-3859.37525","article-title":"Risendronate induced transient ocular myasthenia","volume":"53","author":"Raja","year":"2007","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.avsg.2017.11.037_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.avsg.2017.11.037_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2015.03.018","article-title":"Prognostic factors for exacerbations and emergency treatments in myasthenia gravis","volume":"15","author":"De Meel","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.avsg.2017.11.037_bib9","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00198-014-2768-4","article-title":"Exacerbation of myasthenia gravis by alendronate","volume":"25","author":"Kesikburun","year":"2014","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.avsg.2017.11.037_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48-49","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.avsg.2017.11.037_bib11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mus.23751","article-title":"Exacerbation of myasthenia gravis with voriconazole","volume":"47","author":"Azzam","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.avsg.2017.11.037_bib12","doi-asserted-by":"crossref","first-page":"83947","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluorquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.avsg.2017.11.037_bib13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/mus.22096","article-title":"Myasthenia gravis exacerbation after cetirizine adminsitration","volume":"44","author":"Cobo Calvo","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.avsg.2017.11.037_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mus.21708","article-title":"Gabapentin-induced exacerbation of myasthenia gravis","volume":"42","author":"Sheen","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.avsg.2017.11.037_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0035-1568875","article-title":"Major bleeding and case fatality rate with the direct oral anticoagulants in orthopedic surgery: a systematic review and meta-analysis","volume":"42","author":"Riva","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.avsg.2017.11.037_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1160\/TH14-06-0484","article-title":"Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism","volume":"113","author":"Beyer-Westendorf","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.avsg.2017.11.037_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijcard.2015.11.084","article-title":"Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups","volume":"204","author":"Lip","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.avsg.2017.11.037_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jcpt.12288","article-title":"Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital","volume":"40","author":"Tellor","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.avsg.2017.11.037_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.thromres.2014.05.013","article-title":"Treatment of patients with acute deep vein thrombosis and\/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations","volume":"134","author":"Prandoni","year":"2014","journal-title":"Thromb Res"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089050961830089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089050961830089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T01:53:03Z","timestamp":1535075583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089050961830089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":19,"alternative-id":["S089050961830089X"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2017.11.037","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Myasthenia Induced by Rivaroxaban in Patient with Deep Vein Thrombosis","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2017.11.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}